Literature DB >> 10619854

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

B J Druker1, N B Lydon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10619854      PMCID： PMC382593          DOI： 10.1172/JCI9083

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  27 in total

1.  Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor.

Authors:  T Schindler; F Sicheri; A Pico; A Gazit; A Levitzki; J Kuriyan
Journal:  Mol Cell       Date:  1999-05       Impact factor: 17.970

Review 2.  The structure-based design of ATP-site directed protein kinase inhibitors.

Authors:  L M Toledo; N B Lydon; D Elbaum
Journal:  Curr Med Chem       Date:  1999-09       Impact factor: 4.530

3.  Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.

Authors:  X Zhu; J L Kim; J R Newcomb; P E Rose; D R Stover; L M Toledo; H Zhao; K A Morgenstern
Journal:  Structure       Date:  1999-06-15       Impact factor: 5.006

Review 4.  Protein tyrosine kinases and cancer.

Authors:  K S Kolibaba; B J Druker
Journal:  Biochim Biophys Acta       Date:  1997-12-09

5.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

6.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

7.  Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia.

Authors:  C R Bartram; A de Klein; A Hagemeijer; T van Agthoven; A Geurts van Kessel; D Bootsma; G Grosveld; M A Ferguson-Smith; T Davies; M Stone
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

8.  Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.

Authors:  N Heisterkamp; J R Stephenson; J Groffen; P F Hansen; A de Klein; C R Bartram; G Grosveld
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

9.  Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

Authors:  M Beran; X Cao; Z Estrov; S Jeha; G Jin; S O'Brien; M Talpaz; R B Arlinghaus; N B Lydon; H Kantarjian
Journal:  Clin Cancer Res       Date:  1998-07       Impact factor: 12.531

10.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

Authors:  J B Konopka; S M Watanabe; O N Witte
Journal:  Cell       Date:  1984-07       Impact factor: 41.582
View more
  127 in total

1.  Signaling in leukemia: which messenger to kill?

Authors:  W S Pear
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 2.  Jaks and stats as therapeutic targets.

Authors:  J J O'Shea; R Visconti; T P Cheng; M Gadina
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

3.  Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms.

Authors:  M Ladanyi
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

4.  BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19).

Authors:  C A French; I Miyoshi; J C Aster; I Kubonishi; T G Kroll; P Dal Cin; S O Vargas; A R Perez-Atayde; J A Fletcher
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

5.  MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML.

Authors:  Sukanya Suresh; Lynn McCallum; Wanhua Lu; Noureddine Lazar; Bernard Perbal; Alexandra E Irvine
Journal:  J Cell Commun Signal       Date:  2011-06-03       Impact factor: 5.782

6.  Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis.

Authors:  Yuka Hirose; Hitoshi Kiyoi; Masanori Iwai; Toshiya Yokozawa; Masafumi Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

7.  Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.

Authors:  Arnaldo A Arbini; Margherita Greco; Jorge L Yao; Patricia Bourne; Ersilia Marra; Jer-Tsong Hsieh; Paul A di Sant'agnese; Loredana Moro
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 8.  The role of cost-effectiveness analysis in the era of pharmacogenomics.

Authors:  Christopher R Flowers; David Veenstra
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 9.  Bugs, drugs and chemical genomics.

Authors:  Terry Roemer; Julian Davies; Guri Giaever; Corey Nislow
Journal:  Nat Chem Biol       Date:  2011-12-15       Impact factor: 15.040

10.  Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease.

Authors:  Thomas M Kaiser; Zackery W Dentmon; Christopher E Dalloul; Savita K Sharma; Dennis C Liotta
Journal:  ACS Med Chem Lett       Date:  2020-03-12       Impact factor: 4.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.